Αναφορές εγγραφής

Παραπομπή σε μορφή APA (7η εκδ.)
Golay, J., Ubiali, G., & Introna, M. (2017). The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies. Ferrata Storti Foundation.
Παραπομπή σε μορφή Chicago (17η εκδ.)
Golay, Josée, Greta Ubiali, και Martino Introna. The Specific Bruton Tyrosine Kinase Inhibitor Acalabrutinib (ACP-196) Shows Favorable in Vitro Activity Against Chronic Lymphocytic Leukemia B Cells with CD20 Antibodies. Ferrata Storti Foundation, 2017.
Παραπομπή σε μορφή MLA (9th εκδ.)
Golay, Josée, et al. The Specific Bruton Tyrosine Kinase Inhibitor Acalabrutinib (ACP-196) Shows Favorable in Vitro Activity Against Chronic Lymphocytic Leukemia B Cells with CD20 Antibodies. Ferrata Storti Foundation, 2017.
Πρόσοχή: Οι παραπομπές μπορεί να μην είναι 100% ακριβείς.